NCT03926780View on ClinicalTrials.gov

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi

PHASE3CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Anticoagulants; IncreasedLeft Ventricular Thrombosis
Interventions
DRUG

Rivaroxaban 20 MG

38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day

DRUG

Warfarin Sodium

38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3

Trial Locations (1)

21524

Andalusia Hospitals, Alexandria

All Listed Sponsors
lead

The Young Investigator Group of Cardiovascular Research

NETWORK

NCT03926780 - Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi | Biotech Hunter | Biotech Hunter